MedTrace Logo

Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

NCT04649112 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-07-26

No results posted yet for this study

Summary

This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.

Conditions

  • CD19 Expressing Malignancies
  • Hematologic Malignancy

Interventions

GENETIC

PBCAR19B

Single dose of Allogeneic Anti-CD19 CAR T cells will be injected/infused

Sponsors & Collaborators

  • Precision BioSciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Monika Vainorius, MD · Precision BioSciences, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-16
Primary Completion
2022-12-22
Completion
2023-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04649112 on ClinicalTrials.gov